PURPOSE: To elucidate the performance of transcatheter aortic valve implantation (TAVI) in bicuspid aortic valve (BAV) patients through a systematic review and meta-analysis. METHODS: A systematic literature review was performed by searching eligible articles in PubMed, Medline, EMBASE, Google Scholar and CNKI. Meta-analysis of included case-control/cohort studies was further conducted. Relative risks (RRs) and the corresponding 95% confidence intervals (CIs) were used to compare clinical outcomes of BAV patients and non-BAV patients. RESULTS: A total of 17 articles including eight case reports, four case series and five case-control/cohort studies with 166 BAV patients were analyzed. Device success rate achieved for TAVI in this cohort of BAV patients was 95.2%. The 30-day mortality rate was 8.4%, and the medium-term (range from 6 months to 2 years) mortality rate reported was 17.9%. Overall, the performance of TAVI in BAV patients was comparable to that in non-BAV patients, as reported by the included case-control/cohort studies (30-day mortality rate: RR = 1.05, 95%CI 0.57-1.95, p = 0.87; Device success rate: RR = 1.00, 95%CI 0.95-1.05, p = 0.94; Incidence of moderate to severe paravalvular regurgitation: RR = 1.25, 95%CI 0.85-1.84, p = 0.25). CONCLUSION: The present study suggested that TAVI may be a feasible and safe treatment modality for BAV patients.
PURPOSE: To elucidate the performance of transcatheter aortic valve implantation (TAVI) in bicuspid aortic valve (BAV) patients through a systematic review and meta-analysis. METHODS: A systematic literature review was performed by searching eligible articles in PubMed, Medline, EMBASE, Google Scholar and CNKI. Meta-analysis of included case-control/cohort studies was further conducted. Relative risks (RRs) and the corresponding 95% confidence intervals (CIs) were used to compare clinical outcomes of BAV patients and non-BAV patients. RESULTS: A total of 17 articles including eight case reports, four case series and five case-control/cohort studies with 166 BAV patients were analyzed. Device success rate achieved for TAVI in this cohort of BAV patients was 95.2%. The 30-day mortality rate was 8.4%, and the medium-term (range from 6 months to 2 years) mortality rate reported was 17.9%. Overall, the performance of TAVI in BAV patients was comparable to that in non-BAV patients, as reported by the included case-control/cohort studies (30-day mortality rate: RR = 1.05, 95%CI 0.57-1.95, p = 0.87; Device success rate: RR = 1.00, 95%CI 0.95-1.05, p = 0.94; Incidence of moderate to severe paravalvular regurgitation: RR = 1.25, 95%CI 0.85-1.84, p = 0.25). CONCLUSION: The present study suggested that TAVI may be a feasible and safe treatment modality for BAV patients.
Authors: Paul T L Chiam; Victor T T Chao; Swee-Yaw Tan; Tian-Hai Koh; Chung-Yin Lee; Ving-Yuen See Tho; Yoong-Kong Sin; Yeow-Leng Chua Journal: JACC Cardiovasc Interv Date: 2010-05 Impact factor: 11.195
Authors: Amit Segev; Dan Spiegelstein; Paul Fefer; Amichai Shinfeld; Ilan Hay; Ehud Raanani; Victor Guetta Journal: Isr Med Assoc J Date: 2013-08 Impact factor: 0.892
Authors: Craig R Smith; Martin B Leon; Michael J Mack; D Craig Miller; Jeffrey W Moses; Lars G Svensson; E Murat Tuzcu; John G Webb; Gregory P Fontana; Raj R Makkar; Mathew Williams; Todd Dewey; Samir Kapadia; Vasilis Babaliaros; Vinod H Thourani; Paul Corso; Augusto D Pichard; Joseph E Bavaria; Howard C Herrmann; Jodi J Akin; William N Anderson; Duolao Wang; Stuart J Pocock Journal: N Engl J Med Date: 2011-06-05 Impact factor: 91.245
Authors: Hector I Michelena; Amber D Khanna; Douglas Mahoney; Edit Margaryan; Yan Topilsky; Rakesh M Suri; Ben Eidem; William D Edwards; Thoralf M Sundt; Maurice Enriquez-Sarano Journal: JAMA Date: 2011-09-14 Impact factor: 56.272
Authors: Namal Wijesinghe; Jian Ye; Josep Rodés-Cabau; Anson Cheung; James L Velianou; Madhu K Natarajan; Eric Dumont; Fabian Nietlispach; Ronen Gurvitch; David A Wood; Edgar Tay; John G Webb Journal: JACC Cardiovasc Interv Date: 2010-11 Impact factor: 11.195
Authors: Alec Vahanian; Ottavio Alfieri; Felicita Andreotti; Manuel J Antunes; Gonzalo Barón-Esquivias; Helmut Baumgartner; Michael Andrew Borger; Thierry P Carrel; Michele De Bonis; Arturo Evangelista; Volkmar Falk; Bernard Lung; Patrizio Lancellotti; Luc Pierard; Susanna Price; Hans-Joachim Schäfers; Gerhard Schuler; Janina Stepinska; Karl Swedberg; Johanna Takkenberg; Ulrich Otto Von Oppell; Stephan Windecker; Jose Luis Zamorano; Marian Zembala Journal: Eur J Cardiothorac Surg Date: 2012-08-25 Impact factor: 4.191
Authors: Timm Bauer; Axel Linke; Horst Sievert; Philipp Kahlert; Rainer Hambrecht; Georg Nickenig; Karl Eugen Hauptmann; Stefan Sack; Ulrich Gerckens; Steffen Schneider; Uwe Zeymer; Ralf Zahn Journal: Am J Cardiol Date: 2013-11-09 Impact factor: 2.778
Authors: N Grewal; M C DeRuiter; M R M Jongbloed; M J Goumans; R J M Klautz; R E Poelmann; A C Gittenberger-de Groot Journal: Neth Heart J Date: 2014-09 Impact factor: 2.380
Authors: Antonio H Frangieh; Jonathan Michel; Oliver Deutsch; Michael Joner; Costanza Pellegrini; Tobias Rheude; Sabine Bleiziffer; Albert Markus Kasel Journal: Clin Res Cardiol Date: 2018-06-14 Impact factor: 5.460
Authors: Jonathan M Michel; Antonio H Frangieh; Daniele Giacoppo; Hector A Alvarez-Covarrubias; Costanza Pellegrini; Tobias Rheude; Oliver Deutsch; N Patrick Mayr; P Moritz Rumpf; Barbara E Stähli; Adnan Kastrati; Heribert Schunkert; Erion Xhepa; Michael Joner; A Markus Kasel Journal: Clin Res Cardiol Date: 2021-09-09 Impact factor: 5.460
Authors: Sara Boccalini; Lidia R Bons; Allard T van den Hoven; Annemien E van den Bosch; Gabriel P Krestin; Jolien Roos-Hesselink; Ricardo P J Budde Journal: Eur Radiol Date: 2021-04-24 Impact factor: 5.315